Professional Documents
Culture Documents
MITHST 921S09 Lec08 Hill
MITHST 921S09 Lec08 Hill
Key Issues
ÔThe Market
ÔThe Management
ÔThe Method
ÔThe Money
ÔThe Metrics
2
Venture Capital Deal Flow
Projects
Evaluated
3 Projects Funded
Key Triage Factors
Management Pedigree
Deal Source
Process Management
Customer Validation
Adherence to Plan
4
Key Focus Areas
5
Major Risk Factors
Technological
Market
Regulatory
Operational
6
Market
Macro Micro
ÔSize ÔEconomics (Pricing, Operating Margins)
ÔGrowth Rate ÔCustomers
ÔConcentration ÔSegmentation
ÔBarriers to Enter
7
Methodology
Business Model
Value Proposition
Distribution Strategy
Competitive Differentiation
Growth Strategy
Technology
8
Management
Vision
Education
Track Record
Capability
9
Money
Financial Strategy
Capital Requirements
Structure
Valuation
Liquidity Path
Use of Proceeds
10
Numbers
Income Statement
ÔRevenue Projections ($, Units, Average Sale Price)
ÔExpense Projections (Head Count, Salary Level, Corporate Overhead)
ÔMargins (Gross, Operating)
Balance Sheet
ÔCash
ÔAccounts Receivable
ÔInventory
ÔGoodwill/Intangibles
ÔDebt
ÔLiabilities
11
Cash Flow
ÔOperating
ÔFinancing
Budget
Capitalization Table
ÔInvestors
ÔManagement
ÔOption Pool
12
The Process
Business Plan Review
Management Presentation
Site Visit(s)
References
Competitive Analysis
Financial Analysis
Corporate Review
The Deal
13
Business Plan Review
Form
Substance
Vision
Business Model
Marketing Plan
Technology Plan
Financial Plan
14
Venture Capital Glossary
What We/They say… and What We/They Really Mean…
Acquisition Strategy the current products have no market
Adverse Customer Selection existing customers can’t stand the product; no
positive customer references
Basically on plan revenue shortfall of 25 percent
Dotcom business model potentially bigger fools have been identified
Considerably ahead of plan hit plan in one of the last three months
Currently revisiting the budget financial plan is in total chaos
Cyclical industry posted a huge loss last year
Entrepreneurial CEO totally uncontrollable, bordering on maniacal
Funding Interruption existing investors tapped out and unwilling to
provide additional funding
Ingredients are there given two years we might find a workable strategy
Investing heavily in R&D trying desperately to catch the competition
Limited downside it can’t get much worse
15
Venture Capital Glossary...
What We/They say… and What We/They Really Mean…
Long selling cycle yet to find a customer who likes the product
On a manufacturing learning curve can’t make the product with positive margins
Possibility of a slight shortfall a revenue shortfall of 50 percent
Repositioning the business multimillion-dollar investment recently written off
Somewhat below the plan revenue shortfall of 75 percent
Too early to tell results to date have been grim
Turnaround opportunity lost cause
Unique no more than six competitors
Upgrading the management team the organization is in complete disarray
Window of opportunity without more money, the company is dead
Work closely with the management talk to them on the phone once a month
16
Pipeline Qualification
17
Technology Review
Technology
ÔArchitecture (web-enabled or web-centric) thick
versus thin client
ÔOperating System
ÔRelational Database
ÔApplication Code
ÔDevelopment Environment
18
Technology Review (continued)
Resources
ÔBudget
» Cap Ex
» Development
» Operating
» Maintenance
ÔStaff
» External
» Internal
19
Technology Review (continued)
Track Record
ÔFinance
ÔDevelopment
ÔExperience
20
Technology Review (continued)
Function
ÔPublish
ÔInteract
ÔTransact
ÔTransform
21
Technology Review (continued)
Development Semantics
ÔPre-alpha
» A concept in someone’s mind
ÔAlpha
» Works only in development laboratory
ÔBeta
» Installed in production environment, partial
feature/function complete
ÔFirst Customer Release
» Debugged, defined feature/function shipping to
paying customers
22
Management Presentation
Articulation
Cogent Strategy
23
Site Visit
Headquarters
Outlets
First Impression
Organizational Culture
24
References
25
Competitive Analysis
Market Share
Mind Share
Momentum
Differentiation
Buyer Motivation - Painkiller or Vitamin?
Sales Cycle
Pricing
26
Pricing
Traditional
ÔSoftware License Fee
ÔAnnual Maintenance
Emerging
ÔSubscription
ÔTransaction Based
27
Valley of Death
Gross Margin
28
ASP Pricing Model
Organization Size/
Financial Resources
Financial Barrier
To Adoption
Market
29
Financial Analysis
Sales Pipeline
Valuation
30
Corporate Review
Audit and Management Letter
Legal (Lawsuits, Licensing, Agreements, Distribution
Agreements, Employee Agreements, Employee Benefits,
Shareholder Agreements, Stock Options, Financing
Agreements, Stock Ledger, Customer Contracts, etc.)
Regulatory (Licenses, FDA, Environmental)
Intellectual Property (Patents, Copyrights,
Trademarks)
Insurance (Liability, Key Man, D&O, E&O)
Leases (Real Estate, Capital Equipment)
31
The Deal
Term Sheet
Legal Representation
Document Preparation
Closing
Post-Closing Review
32
Tips
Dos:
ÔConduct site visits of corporate and regional offices’
arrive early
ÔTour with junior (non-management) staff
ÔMeet with worker bees
ÔSee production environment
ÔAsk lots of questions
33
Tips
Don’ts:
ÔMistake development for production
ÔVisit only corporate site and staff
ÔDiscuss anything in elevators or bathrooms
ÔLeave your files unattended
ÔSign the visitor log
ÔLead the witness
ÔVolunteer competitive information
ÔBreach moral/written obligation of confidentiality
34
Human Capital Assessment
Venture Techniques
Art Critic
Sponge
Prosecutor
Airline Captain
35
Management Orientation
Missionary
Mercenary
36
Management Attributes
37
Health Care Drivers
Aging Demographics
Scientific Innovation
Consumerism
Cost Escalation
38
Health Care I/T
Market
ÔSize: Healthcare $1.7T (13.8% GDP) 7% CAGR
Healthcare IT $25B; 12% CAGR
39
Stimulus Bill
Funding: $20B
Recipients: Hospitals/MD’s
40
Health Care I/T
Clinical
F
O
C
Administrative
U
S
Financial
FUNCTION
41
Health Care I/T
High Potential Opportunities
ÔPharmaceutical Services
» E-detailing
» Clinical trial management (Phase Forward)
ÔClinical Systems
» Electronic medical record
» Image management (EMed Technologies)
» Medication management
» Remote physiological monitoring
ÔEmployee Benefits
» Consumer driven
ÔSupply Chain Management
» Exchanges
42
Health Care I/T
Barriers to Adoption
ÔStructural
» Fragmentation
» Decision process
ÔEconomic
» Cost benefit ROI -- Increased revenue
Reduced time
Reduced cost
» Macro – reimbursement
» Micro – margins
43
Health Care I/T
Barriers to Adoption (continued)
ÔOperational
» Work flow integration
ÔTechnological
» Legacy system integration
» Standards: Articulation
Compliance
ÔRegulatory
» HIPPA
ÔAdoption rate
» Crossing the Chasm
44
Innovation Adoption – Life Cycle
100%
A dopters
Late
Market Penetration
n
tio
op
Ad
rly
Ea
Early Chasm
Adoption
0%
Time
45
Adoption
Drivers Enablers
ÔEconomic ÔFinancial
ÔRegulatory ÔRegulatory
ÔPsychological ÔTechnological
ÔDemand ÔStandards
46
Disruptive Technology
47
Technology Evolution - Network
1960s 1970s 1980s 1990s 2000s
Proprietary
tecture
Archi-
(SNA)
Non-proprietary-packet Academic Commercial
(TCPIP)
Government
Content Switches Connect- Speed
KB MB GB
Copper Fiber
49
Technology Evolution - Software
1960s 1970s 1980s 1990s 2000s
Ownership Proprietary Open Source
Language
Text Graphics
Voice
Character Graphic
Input
HST.921 / HST.922 Information Technology in the Health Care System of the Future
Spring 2009
For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.